You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華熙生物(688363.SH):2022年潤致娃娃針已成為各家機構中胚層療法合規必選產品,未來將繼續發力大單品邏輯
格隆匯 04-17 14:29

格隆匯4月17日丨華熙生物(688363.SH)於2023年3月31日15:00召開業績説明會及路演活動,就“醫美業務發展方向?戰略重點?”,公司表示,在醫美業務的持續調整下,對潤致系列未來大單品和組合趨勢充滿信心。①微交聯賽道,2022年潤致娃娃針已成為各家機構中胚層療法合規必選產品,未來將繼續發力大單品邏輯;②填充領域,公司整合潤致產品打造分層抗衰理念,從之前的流量單品轉向提供面部輪廓美學方案為導向的產品組合落地,具體的不同組合取決於醫生針對消費者個性化定製進行。2022年四季度起已經開始在機構試點獲得較高消費者滿意度,主因a.消費者更看重是否能達到變美的結果,b.性價比是否值得支付,c.機構需要持續穩定的毛利,填充劑領域高性價比的產品組合盈利能力優於需要不斷輸出賣點的單品。

醫美事業部同時進行組織架構調整,向解決方案所需能力方面轉移,公司在2022年把部分前端銷售人員轉化為運營賦能專家,幫助機構提升對消費者交付的專業度,通過提升消費者滿意度倒推機構深度合作,深度合作賦能的機構已實現較高進貨率。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account